Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MMJ PhytoTech Limited
ABN	91 601 236 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andreas Gedeon
Date of last notice	3 August 2015

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Greenline Holdings Ltd, a director-related entity.
Date of change	8 July 2016
No. of securities held prior to change	3,750,808 Fully Paid Ordinary Shares 1,875,404 Fully Paid Ordinary Shares (escrowed until 27/10/2016)
Class	Fully Paid Ordinary Shares (escrowed until 28/09/2016)
Number acquired	937,702 Fully Paid Ordinary Shares (escrowed until 28/09/2016)
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deferred consideration for the acquisition of MMJ Biosciences Inc upon the satisfaction of the First Milestone (nil cash consideration). Full details can be found in the Notice of Meeting dated 25 May 2015.

+ See chapter 19 for defined terms.

No. of securities held after change	3,750,808 Fully Paid Ordinary Shares 1,875,404 Fully Paid Ordinary Shares (escrowed until 27/10/2016) 937,702 Fully Paid Ordinary Shares (escrowed until 28/09/2016)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Deferred consideration for the acquisition of MMJ Biosciences Inc upon the satisfaction of the First Milestone (nil cash consideration). Full details can be found in the Notice of Meeting dated 25 May 2015.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	No change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MMJ PhytoTech Limited
ABN	91 601 236 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross McKay
Date of last notice	3 August 2015

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	8 July 2016
No. of securities held prior to change	56,582 Fully Paid Ordinary Shares 28,291 Fully Paid Ordinary Shares (escrowed until 27/10/2016) 1,000,000 Class D Options ($0.40, 27/07/2018)
Class	Fully Paid Ordinary Shares (escrowed until 28/09/2016)
Number acquired	14,146 Fully Paid Ordinary Shares (escrowed until 28/09/2016)
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deferred consideration for the acquisition of MMJ Biosciences Inc upon the satisfaction of the First Milestone (nil cash consideration). Full details can be found in the Notice of Meeting dated 25 May 2015.

+ See chapter 19 for defined terms.

No. of securities held after change	56,582 Fully Paid Ordinary Shares 28,291 Fully Paid Ordinary Shares (escrowed until 27/10/2016) 14,145 Fully Paid Ordinary Shares (escrowed until 28/09/2016) 1,000,000 Class D Options ($0.40, 27/07/2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Deferred consideration for the acquisition of MMJ Biosciences Inc upon the satisfaction of the First Milestone (nil cash consideration). Full details can be found in the Notice of Meeting dated 25 May 2015.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder **(if issued securities)**	
Date of change	No change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MMJ PhytoTech Limited
ABN	91 601 236 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jason Bednar
Date of last notice	3 August 2015

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	8 July 2016
No. of securities held prior to change	586,584 Fully Paid Ordinary Shares 293,292 Fully Paid Ordinary Shares (escrowed until 27/10/2016) 1,500,000 Class D Options ($0.40, 27/07/2018)
Class	Fully Paid Ordinary Shares (escrowed until 28/09/2016)
Number acquired	146,646 Fully Paid Ordinary Shares (escrowed until 28/09/2016)
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deferred consideration for the acquisition of MMJ Biosciences Inc upon the satisfaction of the First Milestone (nil cash consideration). Full details can be found in the Notice of Meeting dated 25 May 2015.

+ See chapter 19 for defined terms.

No. of securities held after change	586,584 Fully Paid Ordinary Shares 293,292 Fully Paid Ordinary Shares (escrowed until 27/10/2016) 146,646 Fully Paid Ordinary Shares (escrowed until 28/09/2016) 1,500,000 Class D Options ($0.40, 27/07/2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Deferred consideration for the acquisition of MMJ Biosciences Inc upon the satisfaction of the First Milestone (nil cash consideration). Full details can be found in the Notice of Meeting dated 25 May 2015.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	No change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.